Mather Group LLC. Acquires 113,358 Shares of Danaher Corporation $DHR

Key Points

• Mather Group significantly increased its Danaher stake by purchasing 113,358 additional shares, a 921.1% increase, bringing its total holdings to 125,665 shares worth approximately $27.8 million.
• Danaher’s latest quarterly results exceeded expectations, with adjusted earnings of $1.94 per share versus the $1.85 consensus and revenue of $6.26 billion, up 5.5% year over year.
• Growth prospects remain supported by AI and automation initiatives, including a collaboration with NVIDIA; analysts maintain a “Moderate Buy” consensus with an average price target of $235.41, compared with the stock’s $224.65 opening price.

Mather Group LLC. increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 921.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 125,665 shares of the conglomerate's stock after purchasing an additional 113,358 shares during the period. Mather Group LLC.'s holdings in Danaher were worth $27,841,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DHR. Marquette Asset Management LLC grew its holdings in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock valued at $25,000 after buying an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC bought a new position in Danaher in the 2nd quarter worth approximately $25,000. Main Street Group LTD bought a new position in Danaher in the 1st quarter worth approximately $25,000. Field & Main Bank acquired a new position in shares of Danaher during the second quarter worth approximately $29,000. Finally, Evolution Wealth Management Inc. lifted its holdings in shares of Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after buying an additional 104 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Up 0.8%

DHR stock opened at $224.65 on Thursday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The company has a market cap of $157.93 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The business's 50-day simple moving average is $212.92 and its 200 day simple moving average is $195.39.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 EPS. On average, research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher's dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DHR shares. Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a research report on Monday. The Goldman Sachs Group raised their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a "buy" rating in a research note on Monday, September 21st. Stifel Nicolaus cut their target price on shares of Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research note on Wednesday, July 22nd. Wells Fargo & Company reduced their price target on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $235.41.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.